Targeting New Molecular Drivers in NSCLC

Targeting New Molecular Drivers in NSCLC

Emerging Data Under the Magnifying Glass

Not a member of My prIME? Join now for instant access.

Meeting Overview

This interactive activity will focus on emerging targeted therapy options for new actionable molecular drivers in non-small cell cancer (NSCLC). Expert faculty will present updates on advances in molecular testing, such as next generation sequencing and liquid biopsy, new data on emerging agents, and how these new data should be applied in clinical practice.

Date and Location

Friday, 9 November 2018
12.15 – 13.45

Jade Ballroom
Intercontinental Guangzhou Exhibition Center
Guangzhou, China



Friday, 9 November 2018



Guangzhou, China



12.15 Welcome and introduction
Tony Mok, MD, FRCPC
12.18 Test your knowledge on new molecular targets and precision therapy for advanced NSCLC
Tony Mok, MD, FRCPC
12.23 Why, when, and how to incorporate broad molecular profiling into routine management of lung cancer
Ming Sound Tsao, MD, FRCPC
12.39 Targeting c-MET in advanced NSCLC
Terufumi Kato, MD
12.55 Targeting HER2, RET, and NTRK
Tony Mok, MD, FRCPC
13.11 Targeting acquired resistance to EGFR kinase inhibitors: Beyond T790M mutation
James C-H Yang, MD, PhD
13.27 Brainstorming session: Integrating new targeted therapies for NSCLC with rare drivers in clinical practice
Faculty Panel
13.43 prIME Points™
Tony Mok, MD, FRCPC
13.45 Adjourn



  • Tony Mok, MD, FRCPThe Chinese University of Hong Kong
    Hong Kong, China
  • Faculty

  • Terufumi Kato, MDKanagawa Cancer Center
    Yokohama, Japan
  • Ming Sound Tsao, MD, FRCPCPrincess Margaret Cancer Center
    Toronto, Ontario, Canada
  • James C-H Yang, MD, PhDNational Taiwan University Hospital
    National Taiwan University Cancer Center
    Taipei, Taiwan

This educational activity is intended for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, oncology fellows, and other healthcare professionals involved in the management of patients with lung cancer in Asia.

After successful completion of this educational activity, participants should be able to:

  • Assess and apply molecular testing methods in advanced NSCLC, including next-generation sequencing (NGS) and use of liquid biopsy
  • Evaluate the role of potential new actionable oncogene drivers such as MET amplification and exon 14–skipping mutations
  • Analyze efficacy and safety data of emerging agents in patients harboring rare driver mutations
  • Explain mechanisms of acquired resistance to EGFR TKIs and strategies for overcoming resistance

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.